デンマーク拠点のバイオ医薬品の製造設備を大幅増強
Fujifilm to invest 928 million USD to expand its large scale biologics production facility in Denmark
- Doubling the drug substance production capacity
- Establishing end-to-end capabilities in one site, including drug substance manufacturing, fill/finish, assembly, labeling and packaging
TOKYO, June 9, 2020 —
FUJIFILM
will make a major capital investment of approximately 928 million USD) in the Denmark site of FUJIFILM Diosynth Biotechnologies,
a leading contract development and manufacturing organization (CDMO) for biologics and advanced therapies.
The capital investment
will double the Denmark site’s current drug substance manufacturing capacity, and will expand its capabilities to include fill/finish, and enhance its current assembly, labeling and packaging services.
FUJIFILM Diosynth Biotechnologies (Denmark)
will expand production lines for bulk drug substance with the addition of a further six mammalian cell bioreactors, bringing the total to 12 x 20,000-liter bioreactors by fall 2023,
making the Denmark facility one of the few major large-scale manufacturing facilities in the bio-CDMO industry.
The development
will also include the addition of the Denmark site’s first fill/finish production line (added by summer 2023),
featuring
a fully-automated, cutting-edge system capable of producing up to approximately 35 million units per annum to cater to large-scale production.
In spring 2022,
a new packaging line equipped with facilities to assemble multiple types of auto-injectors* as well as automatic labeling, will be added to meet a broad range of customer needs.
Since the acquisition of the Denmark site last year, the facility’s strong manufacturing track-record, coupled with FUJIFILM Diosynth Biotechnologies’ technologies enabling a stable supply of high-quality biopharmaceuticals,
has led to new orders not only from existing clients, but also new clients, contributing to our rapid business expansion
In August 2019,
Fujifilm invested approximately 890 million USD to acquire Biogen’s manufacturing subsidiary in Denmark, for its world-class cGMP capabilities and its experienced talent.
The advanced capabilities at the Denmark site has led to promising collaborations including
the recent announcement of future manufacturing capacity reservation by the COVID-19 Therapeutics Accelerator,
an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed-up the response to the global pandemic.
Fujifilm aims to achieve
100 billion yen in sales in its bio-CDMO business ** by fiscal year ending March 2022,
exceed 200 billion yen in sales by fiscal year ending March 2026,
Fujifilm Global